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                                                                 Abstract 
 
The present pilot study aims to compare the knowledge pertaining to ADR reporting systems 
that government doctors and private practitioners gained in a random, tier-II city in India, by 
conducting a questionnaire based survey. Their knowledge of ADR reporting, related 
guidelines and/or regulations, the frequency of ADRs they observe and diagnose, their 
opinion on mandatory reporting by doctors, type of ADRs they would generally report, and to 
whom ADRs should be reported are discussed besides evaluating the attributable reasons for 
underreporting, if any. A total of 47 (21.36%) responded to this random survey, of whom 27 
(57.4%) were government doctors and 14 (29.7%) were private practitioners. Interestingly, 
68.2% of doctors from either groups liked the idea of ADR reporting being made mandatory 
for doctors. The Chi-square test turned out to be significant with  χ²= 26.729, p < 0.05, 
indicating there exists a difference between government doctors and private practitioners 
regarding the types of ADRs they would generally report. Lack of time, unavailability of 
ADR reporting forms, and system of reporting being too bureaucratic were cited as reasons 
for underreporting of ADRs. Creating awareness, among doctors of both groups, about ADR 
reporting via CME programs, offering incentives to reporters, and establishing ADR 
monitoring and reporting systems in hospitals and clinics under the supervision of 
pharmacists will help improve ADR reporting in this selected tier-II city of Warangal, in the 
state of Andhra Pradesh in India.  
  
 Key Words:  Adverse Drug Reaction (ADRs), ADR reporting systems, 
Pharmacovigilance, Central Drug Standard Control Organization (CDSCO), National 
Pharmacovigilance Program (NPP).    
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                                                        Chapter 1: Introduction 
1.1   Introduction 
 
 Effectiveness and efficacy are two attributes of a drug that are sought for whenever 
clinicians choose a drug to cure or treat an underlying ailment. While effectiveness is the 
capacity of a drug to produce known pharmacological effect, efficacy is the ability of a drug 
to produce and reproduce, under ideal circumstances, a desired pharmacological effect. Drugs 
also produce side effects (besides desired pharmacological effects) which are defined as 
normally unavoidable secondary effects of a drug at therapeutic levels/concentrations. These 
side effects, at higher doses or of higher severity are often termed as Adverse Drug Reactions 
(ADRs). Depending upon the severity ADRs can cause even hospitalization or death. The 
International Conference on Harmonization (ICH) Guidelines for Good Clinical Practice 
(GCP) defines ADRs as a response to a drug that is noxious and unintended and that occurs at 
doses normally used in man for prophylaxis, diagnosis, or therapy of diseases or for 
modification of physiological function (World Health Organization [WHO] report 498, 1972). 
 In the recent years, deaths due to adverse drug reactions are increasing (Shepherd, 
Mohorn, Yacoub, & May, 2012; Kieve, 2012). To lower the incidence or prevent those 
deaths, spontaneous reporting of ADR is the best possible way, and Desai et al. (2011) opined 
spontaneous reporting of ADRs as an important tool in pharmacovigilance. They also 
observed that, in daily practice, medical practitioners report very few adverse effects which 
are caused by drugs. According to the authorities at Central Drug Standard Control 
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Organization (CDSCO), hospitalization, disability, and life-threatening reactions caused by 
the drugs need to be reported. But only a small portion of these are officially reported.  
 1.2   Background 
 
 A study conducted by Schneeweiss et al. (2002) shows that 5 to 10% of patients were 
admitted to hospitals as a consequence of ADRs.
 
In several studies the frequency was 
estimated to be 20% of all cases admitted to the geriatric department as well as in the internal 
medicine departments.
 
 
A study conducted by Lazrou, Pomeranz, and Corey (1998) concludes that incidences 
of serious ADRs reported were 6.7% and fatal ADRs were 0.32% of hospitalized patients. 
They also estimated that in the year 1994, a total of 2,216,000 hospital consumers had serious 
ADRs and about 106,000 hospital consumers had experienced fatal ADRs, making them the 
fourth to sixth leading cause of death in the United States. 
             A study conducted by Routledge and co-worker (2004) concludes that the expenditure 
of ADRs has been anticipated to be as a high as ₤ 0.5 billion each year in the United Kingdom 
(UK) due to the prolongation of hospital visits.  
 Ramesh, Pandit, and Parthasarathi (2003), in their study conducted in a south Indian 
hospital, reported that 0.7% of hospital admissions were because of ADRs and of the 3.7% in-
patients who suffered an ADR, a total of 1.3% were fatal. Another study conducted by 
Arulmani et al.(2007) recorded a 3.4% of ADR related admissions into hospital and 3.7% of 
recorded ADRs during hospital stay in nine months. An observational study conducted by 
Singh et al. (2010) revealed that in a tertiary care facility (in Northern India) there were 154 
ADRs reported over a period of 6 months, which reiterates the regular occurrence of ADRs. It 
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was also reported by Arulmani et al. (2007) that ADRs and related hospitalizations prove a 
financial burden on the hospitals and thus on the State. They calculated the average cost per 
ADR per patient to be ₹ 481 (£6) while Ramesh and co-workers calculated the average cost in 
managing reported ADR (per ADR) to be ₹ 690 ($ 12.5). 
 It's possible that some or many other ADRs might have gone unreported during the 
course of the above referenced studies. There are various reasons, as cited by researchers, for 
ADRs being not reported to the extent they should. A few are as follows: 
- Lack of knowledge with regard to the guidelines/regulations of ADR reporting 
- Lack of clarity regarding the responsibility (is it up to the doctor or to other medical 
staff [pharmacists/nurse] to report ADRs?) 
- Too busy to report ADR/ ignorance with respect to ADR reporting  
- Malfunctioning of an established ADR reporting system (unavailability of required 
forms), and so on. 
 Desai et al. (2011) evaluated the KAP (Knowledge, Attitude and Practice) of 
prescribers with regard to ADR reporting and found that though the attitudes are positive, 
practice is lacking, citing some of the above reasons. Many studies were conducted to 
evaluate the practice of ADR reporting in various parts of India and to suggest methods to 
streamline the system. Sampling studies were conducted in many metropolitan and 
cosmopolitan cities like Mumbai, Mysore, Ahmedabad and so on, but a perfect figure would 
only be obtained when random studies are also taken up in tier-II and tier-III cities. In an 
effort to understand the general trend of the ADR reporting system in those tier-II and tier-III 
cities and to contribute to the general understanding of the knowledge of ADRs and its 
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reporting systems across India, this study was proposed. Methodology was similar to other 
studies. The survey questionnaire was administered randomly to prescribers and the statistical 
methods like Student T- test and Chi-square test were used. Prime motive of this research was 
to study and understand the general trend of this ADR reporting system in a randomly 
selected tier-II city, analyze restraints to this system (if any), and suggest ways to establish a 
perfectly functional system, if need be. This research study could serve as a foundation study 
in the randomly selected city in tracking the trend of ADR reporting system and in suggesting 
changes (if needed) from time to time. 
1.3   Purpose  
 The present study was undertaken to investigate the knowledge that private 
practitioners and government appointed doctors gained about the ADR reporting system 
and/or the guidelines thereof, in a random locality (a tier-II city) in India. 
1.4   Objectives 
1.4.1  Primary Objective (Research Question) 
 Are the doctors (both private practitioners and government appointed) in a random 
locality in India familiar with ADR reporting system (and/or guidelines/regulations)? If yes, 
do they take responsibility in reporting ADRs or do they rely on their staff to do so? 
1.4.2  Secondary objective: 
- To determine the factors responsible for under-reporting of ADRs (if any) 
- To suggest ways of increasing the ADR reporting 
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1.5   Hypothesis 
1.5.1. Null Hypothesis (Ho): All doctors, both private and government-appointed doctors, 
have enough knowledge of the guidelines/regulations for ADR reporting and they do take 
responsibility in reporting ADRs to pharmacovigilance authorities or the pharmaceutical 
companies. 
1.5.2. Alternate Hypothesis (H1): There is a difference in the knowledge that private 
practitioners and government doctors have regarding the guidelines/regulations of ADR 
reporting and the clarity they have regarding the responsibility of ADR reporting. 
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                                                 Chapter 2: Literature Review  
2.1   Definition of Adverse Drug Reaction 
 
 The WHO, in its technical report series (WHO report 498, 1972), defined an Adverse 
Drug Reaction as "noxious, unintended and which occurs at dosages normally used in human 
beings for prophylaxis, diagnosis or therapy for the disease or for the modification of the 
physiological function." Allergies, idiosyncrasies, pharmacological and toxicological 
mechanisms, and interactions between different drugs were also included in the definition 
with them being independent of the mechanism of ADR. The former was later adapted by the 
ICH- GCP as their definition of an ADR. Parker (1982) opined that ADR might involve 
immunological or non-immunological mechanisms as well. 
2.2  Classification of ADRs 
 
 Until recently most of the researchers followed the conventional classification of 
ADRs by Rawlins and Thompson (1977). Some of the researchers, prescribers, and 
pharmacovigilance professionals extrapolated the classification of ADRs based on works of 
Rawlins and Thompson (1977) and Naranjo et al. (1981). The classification of ADRs is still 
being researched owing to the fact that new kinds of ADRs are being reported that do not fit 
into any other previous classifications. 
 The conventional and probably one of the first classifications of ADR by Rawlins and 
Thompson (1977) divide adverse reactions into Type A reactions (also termed as augmented 
reactions), which are the undesired pharmacological effects of drugs and are dosage-
dependent, and which are predictable and thus preventable too. Some examples of this type 
are bradycardia-with the use of beta blockers, hemorrhage-with use of anticoagulants, and 
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drowsiness-with benzodiazepines. Though Type A reactions depict rather high incidence and 
morbidity, associated mortality is comparatively low. Inevitably, unpredictable reactions with 
an unknown pharmacological mechanism at normal dosages were grouped into Type B 
(Bizzare). One example is malignant hypothermia upon administration of general anesthesia. 
The associated mortality rate was said to be high with these Type B ADRs while the 
incidence rate and morbidity were comparatively low. 
 Edwards and Aronson (2000)  further expanded the classification of ADRs into: 
 Type C - reactions associated with prolonged therapies for chronic 
ailments/diseases. One example is analgesic nephropathy  
 Type D - uncommon delayed reaction that become apparent only after an elapsed 
period of time and those which are dose dependent. Examples are carcinogenesis 
and teratogenesis  
 Type E - reactions that are associated with the withdrawal of drugs. Examples 
include antidepressant discontinuation syndrome associated with the withdrawal of 
Serotonin Nor-epinephrine Re-uptake Inhibitors (SNRIs) or other class of Selective 
Serotonin Re-uptake Inhibitors (SSRIs) 
 Type F-  Failure of therapy owing to intrinsic properties of drugs, which are dose-
related and supposed to be caused by drug interactions 
 Naranjo et al. (1981) devised a method to estimate the causality of ADRs and 
classified them based on the probability of causality as definite, probable, possible, and 
doubtful. This mode of classification helped clinicians and pharmacists reach consensus in 
assessing and reporting ADRs.   
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 Hunziker et al. (2002), relying on the conventional classification of ADRs by Rawlins 
and Thompson (1977), classified ADRs based on the largely accepted, contemporary, 
pathomechanisms into Type A1  -   Type A7  and Type Ba (allergic/immunological reactions) 
and  Type Bpa. (pseudo allergic/anaplylactoid reactions): 
 Type A1 : reactions not specified in Type A 
 Type A2 : dose related reactions 
 Type A3 : patient related reactions - Idiosyncrasies 
 Type A4 : drug related (intolerance to drugs example: patients allergic to 
penicillins) 
 Type A5 :  drug-to-drug interactions  
 Type A6 :  rebound or withdrawal effects  
 Type A7 :  secondary reaction to drugs 
 This was one of the most comprehensive classifications of ADRs encompassing many 
mechanisms and types of reactions. This sort of classification would help manage the drug 
market with more efficacy by assisting clinicians and pharmacists in the detection of ADRs 
with accuracy. This in turn would encourage the healthcare professionals to indulge more in 
ADR reporting than before.  
2.3   Concept of Pharmacovigilance: Origin      
 
 Pharmacovigilance, a science of activities relating to the detection, assessment, 
understanding, and prevention of adverse drug reactions or any other drug-related problems, 
evolved in the mid-1900s (WHO, 2002). Collecting numerous data related to a product's 
actions, that is, drugs' life cycles, both pre-market and post-market, is the most important part 
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with a concern to public safety. One of the important tools in this area of science is the 
spontaneous reporting of ADRs either by clinicians or the pharmacists. This aids in an 
exceptional management of various diseases using drugs. A brief review of unfortunate events 
in the past associated with drugs will help understand the importance of pharmacovigilance 
whilst giving a clear picture of the conception of this skill. 
 Elixir Sulfanilamide, effectively used in the treatment of streptococcal infections, in 
the year 1937 made it to the headlines in the radio and print media for it was responsible for 
the death of more than 100 patients (both adults and children) within a period of two months. 
Sulfanilamide tablets and powder were used safely in patients and had dramatic curative 
effects, which reiterated that Sulfanilamide was not to blame. The elixir mixture contained 
diethylene glycol, an anti-freeze agent used in automobiles, a potent toxic chemical. This 
chemical was used in the elixir mixture as Sulfanilamide dissolves in this chemical and that 
the mixture had good taste, flavor, and texture. Barely any toxicological studies were 
performed on this new preparation, perhaps owing to fact that sulfanilamide was already 
being effectively used. This episode warranted a swift action on the part of FDA which 
accelerated the final enactment of the Federal Food, Drug, and Cosmetics Act 1938 
(Ballentine, 1981).  
 Supposedly, the first need and/ or act of ADR reporting followed the death of a 15-
year-old girl due to ventricular fibrillation upon administration of general anesthetic 
chloroform in the year 1948. With the concerns of public health and profession about 
anesthetic safety, The Lancet set up a commission inviting doctors from within Britain and its 
colonies to report any anesthesia related deaths (Routledge, P., 1998). This event was marked 
as the origin of the concept of pharmacovigilance on a national scale.  
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 Chloramphenicol (bacteriostatic antimicrobial) had a Type B, unpredictable ADR 
associated with its administration. Upon a series of aplastic anemias detected after the 
administration of chloramphenicol in 1950, the drug was subjected to further pharmacological 
studies after it was marketed. Kramer (1981) cited more examples like chloramphenicol, 
highlighting the importance of continuous studies on a drug's behavior in various populations 
in different situations that do not come under the purview of clinical trials. Clinical trials have 
always been in a conditioned and controlled environment where a drug undergoes rigorous 
testing only in select populations in limited numbers. On the other hand, they are not tested in 
those populations in which they are marketed and used. These contrasting environments in a 
drug's life cycle warrants a pharmacovigilance program in force for efficient management of 
diseases and, in turn, the life cycle of a drug.  
 Thalidomide is another example. Phocomelic babies were born when pregnant woman 
were treated with thalidomide for their acute morning sickness during pregnancies. This was a 
Type-D ADR according to Edwards and Aronson's (2000) classification of ADRs. 
Thalidomide was later withdrawn from the market because of its teratogenic effects upon 
receiving numerous ADR reports from physicians. German physicians published thalidomide 
issue in various journals. McBride (1961) stated that this event associated with thalidomide 
drove many developed countries to establish an organized and systematic evaluation system 
of drugs and associated-ADRs. These systems, in totality, were dependent on physicians and 
pharmacists. Sweden, Canada, the Netherlands, New Zealand, and Australia were the first to 
implement a naïve pharmacovigilance program, and many other countries followed. Gay 
(1997) published astonishing facts about the uses of such pharmacovigilance programs in her 
article. Upon withdrawal from the market, thalidomide was subjected to various other studies; 
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long-term effects of this drug were also studied and by chance it was discovered that this drug 
could be used in treating Erythematic Nodusum Leprosy (ENL). Upon satisfactory results in 
trials, thalidomide was re-introduced in the market for treating leprosy. It was learned that 
thalidomide is effective in treatment of HIV and some cancers; trials are underway and under 
the scrutiny of the FDA. These by-chance discoveries were attributed to the success of 
pharmacovigilance programs as new information regarding the drugs in question would be 
gathered with each and every ADR reported.  
2.4  Established ADR systems across the world 
  2.4.1   United Kingdom  
 
 In the aftermath of the thalidomide event, the Committee on Safety of Drugs (CSD) 
was established in the United Kingdom in 1963, which was later transformed into the 
Committee on Safety of Medicines (CSM) in1968, in the purview of the Medicines Act of 
1968. Since 2005, CSM has become CHM- Commission on Human Medicines which 
provides independent expert advice to the MHRA (Medicines and Healthcare products 
Regulatory Agency) on safety of drugs. Any new chemical entity or vaccine is effectively put 
on a two-year probation by the MHRA with a black triangular caution symbol in the product 
labeling, warranting a strict follow-up on the effectiveness and safety of medicines, by the 
prescribers/doctors, during the probationary period. This will effectively give a chance to 
collect much more data than those collected during the clinical trials on potential and/or 
possible side effects upon longer exposure to the drug. The black triangle mark is not 
removed by the MHRA unless the drug shows satisfactory safety profile in larger populations. 
The black mark may also be placed on new formulations of marketed drugs. On the other 
hand, MHRA mandates pharmaceutical companies to closely monitor the side effects caused 
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by their marketed products. Besides doctors and manufacturers, MHRA also requests patients 
to report potential side effects to OTC (Over The Counter) products and prescription 
medications via the Yellow card scheme (retrieved from www.mhra.gov.uk). All information 
pertaining to the demographics of reporter, drug therapy treated upon, route of administration 
of the drug, dose specification, diagnostic report, and description of reactions, along with 
contact information, is sought while using the Yellow card system (Breckenridge et al., 1998; 
Jefferys et al., 1998; Moore et al., 1985).  
      2.4.2  United States of America 
 
 The Federal Food & Drug Administration (FDA), being the primary governing body 
to regulate the pharmaceutical and medical devices industry, has a dictum to investigate and 
publish information on adverse drug events associated with approved products on the market. 
In order to serve this purpose, FDA has established a service: Adverse Events Reporting 
Service (AERS/FAERS) called MedWatch. (Craigle, 2007). MedWatch is primarily a 
reporting tool focusing on medical devices and medicines with two main purposes: AERS 
tools for use by medical professionals and the public to report adverse events and medical 
injuries associated with products. They provide information to the public on the following: 
prescription drugs, OTC drugs, biologics, medical and radiation-emitting devices, and special 
nutritional products, such as infant formulas and dietary supplements. 
 MedWatch achieves FDA's purpose by encouraging medical professionals and the 
public to voluntarily report any adverse events and/or medical injuries, but for the industry 
(including drug and device manufacturers, importers, and medical facility users) it is 
mandatory to report these events as required by law. MedWatch has the reporting form hosted 
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on their website www.fda.gov/medwatch/getforms.htm, making it easily accessible and 
downloadable from the website. The forms may be downloaded, duly filled in, and sent via 
email, fax, or regular mail. Special dial-in numbers are available to verbally report any AEs 
(Kessler, 1993).         
 Upon receiving reports pertaining to a single drug or medical device, the FDA 
summons more studies into those events whilst temporarily pulling out those products from 
the market. The FDA also sends "Dear health care professionals" letters to medical 
practitioners warning them of the discovered adverse events and requesting them to refrain 
from prescribing "products in question" until more research is done. The FDA holds the 
authority to withdraw the market approval, permanently, in case the products cannot be 
altered to rectify the problem. MedWatch serves as an impeccable tool for the prescribers in 
learning more about the trend in prescription drugs, that is it serves as a CEP (Continuing 
Education Program) tool as well. More importantly, it is a nationwide single authority that 
pools information on AEs rather quickly and at one place, allowing for swift action in the 
interest of public safety. Craigle (2007) mentioned, after reading IOM's report, about the 
alarmingly high $3.2 billion lost in maintaining AE-related injuries. This loss in economy in 
the form of Medicare/Medicaid budgets and lost wages could be addressed rather quickly with 
the aid of such an important reporting tool. The reporting tool, being available over the 
internet, helps PI's (Principal Investigators)/prescribers from across the globe, working on 
offshore trials (under the FDA's regulatory guidance) of drugs meant also to be marketed in 
the USA, to report AEs/associated problems, directly, which has become a huge advantage. 
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2.4.3   Republic of India 
 
 Pharmacovigilance in India started in the year 1986 with the establishment of 12 
regional centers that oversee areas with population sizes of approximately 50 million each 
(Kulkarni, 1986). These centers were vested with the authority to collect formal ADRs but 
failed to do so. In 1997, India Joined WHO's ADR reporting program based in Uppsala, 
Sweden, in order to participate healthily and to contribute to the effort. In 2005, the Ministry 
of Health and Family Welfare in India initiated the National Pharmacovigilance Program 
(NPP), coordinated by the Central Drugs Standard Control Organization (CDSCO) based in 
the national capital, New Delhi. This new program was established because of the failure of 
earlier attempts at pooling ADR reports on a national scale. The established NPP was again 
reviewed in July 2010 according to Biswas and Biswas (2007) and Gupta (2010). NPP was 
visualized to be rolled out in three phases: 
 Phase I - to include 40 ADR Monitoring Centers (AMCs) in the program 
 Phase II - to get 140 MCI (Medical Council of India) recognized medical colleges 
and teaching hospitals involved in the program by the end of 2011 
 Phase III - to orchestrate and weave the program into the healthcare by the end of 
year 2013 
  ADRs collected at the AMCs will be relayed to the regional coordinating centers, 
which then would report the same to the Uppsala monitoring committee. The collected ADRs 
would be analyzed, and the data generated would be used to assess risk patterns, if any, like 
the population at risk. NPP will then circulate the data within the regulatory agencies, 
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allowing them to update warnings and drug labeling. So far, only 24 regional centers have 
been established in the country to serve NPP's purpose.  
 A close comparison of the US and UK pharmacovigilance programs with that of the 
Indian program reveal the fact that NPP in India is still at its infancy, and only in its first 
phase since its establishment in 2005. When compared with the rest of the world, ADR 
reporting percentage in India is only 1% (Prakash, 2007). One of the major reasons for this 
could be unawareness of ADR reporting guidelines/regulations on the part of the 
prescribers/medical practitioners. Another reason could be poor literacy rate of the population 
affecting their ability to read and understand drug labels and cautions written on the labels, 
and lack of support from the government at the county/district level to make it a success. 
Needless to say, incorporating pharmacovigilance concepts into the already extensive syllabi 
of Indian medical and pharmacy schools will be a difficult process for state governments. 
Nonetheless, doing so will equip medical/pharmacy professionals with tools to identify ADR 
signals during the first phase of clinical trials. Instituting a spontaneous ADR reporting 
system on par with those in the developed countries would be ideal for India as data of ADRs 
associated with marketed drugs can be pooled and analyzed rather easily and in short period 
of time with the help of spontaneous reporting tools, which in turn will help update the 
labeling on the drugs. This will help to lower the rate of morbidity and mortality besides 
reducing the budget spent on ADR management on the whole.  
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2.5   Past studies on ADR reporting systems (a review) 
 
  Numerous studies conducted in various parts of the world indicate that ADR reporting 
is not satisfactory, and has not reached the anticipated level in the nations with established 
pharmacovigilance programs. In the United States of America, Rogers et al.(1988) studied the 
knowledge, attitude and practice of 3000 physicians using a questionnaire. Out of the 1121 
(37.3%) physicians that responded only 638 (57%) physicians knew about the FDA's 
established ADR reporting system. However, the study concluded that many of the physicians 
felt the reporting system was inconvenient. This inconvenience in the reporting system's 
functioning or the use of reporting system could lead to a prevalent underreporting of ADRs. 
While in another meta analysis conducted on a 32 year data on ADRs, Lazarou et al.(1998) 
concluded that 6.7% of ADRs reviewed were serious and 0.32% were fatal. They estimated 
that ADRs are one among the six leading causes of death in the United States of America. In a 
situation where ADRs contribute in a good proportion to mortality, poor practices of ADR 
reporting proves as a financial burden on the nation, besides being a threat to the lives of the 
public. 
 In the United Kingdom, Belton, Lewis, Payne and Rawlins (1995) studied 500 
randomly selected doctors from the 1992 Medical Directory of UK to investigate their attitude 
towards CSM's ADR reporting scheme. They assessed the understanding of the doctors about 
the scheme and tried to identify the possible reasons behind underreporting of suspected 
ADRs. Out of the 284 (57%) respondents only 179 (63%) were stated to have previously 
reported ADRs to either the CSM or to pharmaceutical companies. They assessed that, though 
the number of reporting doctors was higher compared to other studies, a significant 
percentage of doctors lacked an understanding of the CSM's yellow card system, which they 
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thought was contributing to the underreporting of ADRs. They reported lack of time, lack of 
reporting forms and a misunderstanding on the part of doctors in maintaining confidentiality 
in the diagnosis of ADRs as the reasons for underreporting.  
  In India, Singh et al.(2010) observed the trend of ADR reporting with respect to a  
poly pharmacy at a tertiary care facility in Northern India and found that in a period of six 
months there were 154 ADRs recorded of which 23 (14.9%) were fatal. Gupta and Udupa 
(2011) cited only 2.9% of ADRs being reported in the city of Mumbai despite 90% resident 
doctors deemed it important to report ADRs to regional centers. They found that the resident 
doctors did not have adequate knowledge about the reporting responsibilities, type of events 
to be reported and mechanism of ADR reporting. They also cited the resident doctors' 
perception of the reporting process being time consuming, lack of knowledge and expertise as 
reasons for underreporting. Upadhyaya, Seth, Moghe, Sharma and Ahmed (2012) reported 
poor knowledge among postgraduate medical students regarding ADR reporting in India. 
They reported only 50% of the students were taught about ADRs and associated reporting 
system while only 50% were reported to have witnessed ADRs during their training. They 
suggested need to periodically check on the knowledge of ADR reporting of the medical 
students. Rehan, Vasudev and Tripathi (2002) in another study, suggested a need to improve 
the Knowledge, Attitude and Practice of medical students, despite the study revealed an 
adequate knowledge of ADR reporting among the students.  
 However, numerous studies conducted all through India have consistently shown poor 
practice or attitude among medical practitioners regarding ADR reporting despite their 
adequate knowledge about the system. Commonality among all the cited studies was that they 
were performed in metro or cosmopolitan cities. Very few, if any, were performed in tier-II  
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and tier-3 cities which only would give us a complete picture of the current National 
Pharmacovigilance Program's success so far. 
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                                                     Chapter 3: Methods 
3.1  Study design 
 
          The study was designed as a cross sectional, observational, questionnaire based survey. 
A questionnaire was drafted based on earlier studies and in a way that best suites the Indian 
setting and the locality in question. All subjects could answer the questionnaire with ease. The 
questionnaire was administered to over 200 subjects, selected at random, so as to represent the 
sample (tier-II city selected) under study, and to have statistical validity. 
3.2  Setting   
 
          The study was conducted in Warangal, a tier-II city in the southern-Indian State of 
Andhra Pradesh, inhabited by a population of 865,527 (Census of India, 2004). A total of over 
820 medical practitioners, distributed throughout the city, provide medical care (through 
various specialties) to the population ( IMA - Warangal branch). The study was conducted 
over a period of three months from October, 2012 to December, 2012. Entire area of the city 
of Warangal was covered which included East, West, Southwest and the Central zones.  
3.3   Questionnaire Development 
 
           A questionnaire consisting of 33 questions framed under six sections was prepared, 
adapted from previous studies on ADR reporting systems in India. However, the final 
questionnaire for the present study was unique in many regards to suit the purpose of the 
study and Indian setting. The questionnaire was structured to collect the demographics of the 
respondents (subjects of study) limited to their gender, field of study, specialty, type of 
practice and their experience, to start with. The rest of the questions were framed under 
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sections-A through section-E that were designed to test the knowledge, attitude and current 
practice of doctors with regards to ADR reporting in the locality. A total of twelve questions 
were designed to evaluate the knowledge, three questions to test the experience they gained, 
three questions to assess their attitudes towards ADR reporting and ADR systems, six 
questions to evaluate their practice of ADR reporting and six questions to understand the 
factors, in their perspective, posed as a hindrance in an efficient pharmacovigilance program. 
(Appendix A). 
             Questions on knowledge would help in gaining information with regards to 
understanding the concept of pharmacovigilance, ADRs and guidelines and/or regulations 
pertaining to the ADR reporting system by the prescribers in the locality. Questions oriented 
on the practice of ADR reporting system and its establishment in a hospital/clinic gave an 
insight into current practices of pharmacovigilance by the practitioners as well as governance, 
with respect to ADRs, by the Health Administration in the locality. Two questions were 
structured specifically to understand how willing are the prescribers to take upon the 
responsibility of screening, diagnosing and reporting ADRs. A series of six questions were 
framed into a section that covered various factors, as possible reasons, in the prescribers' 
perspective. 
            In order to maintain confidentiality about the participants, the entire questionnaire was 
designed to maintain anonymity. Design of the questionnaire includes consideration of 
question format that is, open-ended or closed ended. Provision was also made for suggestions 
on ADR reporting system and its establishment within hospitals and clinics besides specifying 
the reason for not having the system established in the first place.  
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3.4    Approval of the study 
 
              An approval for this study was obtained from the Human Subjects Research Review 
Committee (HSRC), College of Health and Human Services at Eastern Michigan University 
on October 11, 2012 with respect to the initial submission made on August 27, 2012 (file # 
MS 1083)  to comply with the guidelines of human subjects research established by the 
Eastern Michigan University (Appendix B). 
3.5    Subjects 
 
              A total of 220 doctors were chosen randomly, from among 820 registered medical 
practitioners serving the locality. A list of contacts of all those registered practitioners was 
requested from the secretary of IMA (Indian Medical Association- Andhra region, Warangal 
Chapter). The contact list was edited (de-identified) to only include contact e-mail id's of the 
doctors and sorted for common id's, if any. Later 220 doctors were selected randomly using 
their contact email id's. The selected doctors included both government appointed and private 
practitioners.  
3.6   Inclusion and Exclusion Criteria 
 
             An email was sent to each of these selected doctors with HTML link to the online 
survey. A letter accompanied each of these emails with a note for their informed consent. It 
was the doctors decision either to participate or withdraw from the study. Those who were not 
willing to participate in the study were suggested not to respond to the email sent. Those who 
had registered their response were deemed to have voluntarily participated in the study. 
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Subjects were also informed that in case they wished to participate but have lost the HTML 
link previously sent, they could request the HTML link via email and the same was furnished 
in the letter document that accompanied the emails. (Appendix C). 
             No specific inclusion and exclusion criteria were followed in the enrollment of 
subjects into this study except that subjects who did not answer the questionnaire were 
automatically deemed as excluded from the study. 
3.7  Data collection and Statistical analysis 
 
           The questionnaire was validated by reviews from research guide, Dr. Irwin Martin and 
practicing doctors. Questionnaire was distributed to ten doctors and were given a period of 
four days to answer. They were requested to note the time taken to answer the questionnaire 
in full and were requested to express their perspective on the suitability of the questionnaire to 
local setting. Upon satisfactory feedback, the questionnaire was distributed without any major 
changes. Those ten recorded responses were added to the original data collected.  
            The questionnaire was distributed to all the subjects via email and were asked to 
register their responses in their free time. Considering the busy schedules of practicing 
doctors, all responses recorded in a 60 day time period were considered for the study, this was 
to give ample time for the subjects to participate in the study and to encourage non-
respondents to participate in the study. Reminder emails were sent to non-respondents once in 
every two weeks. Responses recorded later than December 15, 2012 were not considered for 
the current study.   
           Data collected were analyzed using a software -Statistical Package for Social Sciences 
(SPSS) version 21.0. Results of the study were presented with descriptive measures such as 
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mean ± standard deviation (for quantitative variables), median (for time related variables) and 
numbers with percentages and/or graphical presentations for categorical variables. All 
statistical analyses were performed at the Power of test at 80% and P value-0.05. Student T- 
test was used to compare means of two continuous variables. Chi-square test was performed 
to find the significant difference between the knowledge in ADR reporting system of private 
practitioners and government appointed doctors. Chi-square test was also used to find out the 
association between two attributes for yes or no questions at P< 0.05 significant level. Item 
scores were awarded and were added together to create a composite score to find out the 
significant difference between those two groups. 
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                                                              Chapter 4: Results  
       4.1   Demographic data 
        4.1.1  Response Rate  
 
  The survey was distributed to 220 doctors out of which 47 responses were registered, 
giving a 21.3% response rate. 30 respondents were male (64.8%) and 17 were female 
(36.2%). See Table 1. 
Table 1: Frequency distribution of gender of participants 
Gender Frequency Percentage 
Female 17   36.2 
Male 30   63.8 
Total 47 100.0 
 
 
 This response rate was achieved only after reminders were sent at regular intervals 
(once in every two weeks) during the study period. More responses were recorded, 
comparatively, immediately after the reminders were emailed. 
 
4.1.2   Type of Practice and Experience  
       
 A total of 27 subjects who responded to the study were doctors working in the 
government sector, that is in government run hospitals and/or clinics, which is an healthy 
57.4%. On the other hand, a total of 14 (29.7%) respondents were private medical 
practitioners. See Table 2. 
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Table 2:  Experience of study subjects in their respective specialties in medicine. 
 
S.No 
 
Experience 
(in Years) 
Government  
practitioners 
Private practitioners  
Total 
 
Percentage 
(% ) 
 
 
 
Male 
 
Female 
 
Male 
 
Female 
  
1 
2 
3 
4 
 
<1  
1 - 5 
5 - 10 
> 10 
 
 
3  
5 
6 
2 
 
 
0 
3 
2 
6 
 
 
2 
5 
3 
2 
 
 
0 
1 
1 
0 
 
 
  5 
14 
12 
10 
 
 
   12.2 
   34.2 
   29.3 
   24.3 
 
 
Total  16 11 12 2 41 100.00  
     
 The rest of the six (6) responses recorded were by the staff of doctors. Five (5) of them 
were pharmacists and one (1) was a staff nurse. All the pharmacists worked in the private 
sector, of whom two (2) were male pharmacists and three (3) were female pharmacists. All 
pharmacists who responded to this survey on their doctors' behalf had 1 - 5 years of 
experience. The staff nurse who answered the questionnaire had greater than 10 years 
experience. The percentage response of non doctors was calculated to be 12.7% . 
 
 Average experience of both government doctors and private practitioners were 
calculated to be 6.75 years and 3.5 years respectively and the median of experience was 5.12 
years. Combined average experience of male doctors was 7 years and that of female doctors 
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was calculated to be 3.25 years. However, there were a total of 6 (14.6%) female doctors with 
greater than 10 years of experience when compared to 4 (9.7%) male doctors with the same 
years of experience. Out of them, only 2 doctors had a private practice, the rest were working 
in the government run hospitals. A graph was plotted with number of practitioners against 
their years of experience in both private and the Government hospitals/clinics to observe a 
pattern, if any. Results are shown graphically in Figure 1. 
Figure 1: Line graph showing differences in the range of experiences gained by doctors (male 
and female) in the government sector and private sector. 
               
  
 It is clearly evident from the graph that, comparatively, government doctors had more 
experience than the private practitioners. It was found that there were only two female doctors 
who have a private practice while there were 11 working on government run hospitals/clinics. 
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4.1.3    Specializations of respondents 
  
  It has been observed that 6 (12.7%)  non-doctors have registered their responses on 
behalf of doctors whom they worked for. Assuming the fact that surveys were administered 
only to doctors, it hints that the doctors were too busy to answer the questionnaire and instead 
had their support staff answer the same which was anticipated. The other 40 (85%) of the 
responses were by doctors who specialize in different areas of medicine (Figure 2). A trend 
has been observed though. Doctors belonging to super specialties like Cardiology, Neurology 
and Endocrinology made up only 8% of the registered responses. Most of the responses were 
registered by people practicing internal medicine /OBGY/pediatrics/orthopedics.   
 
Figure 2: Distribution of number of respondents to survey by their specialization and type of 
practice 
 The graph validates random distribution of the survey with respect to the specialty of 
respondents with the fact that doctors specializing in Medical pharmacology, 
forensic medicine and Ayurvedic medicine were also surveyed. 
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4.2   Adverse Drug Reaction reporting - Knowledge 
 
 There were mixed responses from subjects to questions in this section. The responses 
are distinctive: 33 subjects (70%) reported they have observed ADRs in the past twelve 
months of which only 27 (57%, n= 47) diagnosed ADRs. More importantly, only 23 (48.9%) 
subjects have reported ADRs to either pharmacovigilance centers/pharmaceutical companies.  
The survey indicated that majority of the subjects observed less than 25 ADRs in a six month 
period. On the other hand, only 13% reported ADRs to pharmacovigilance centers and 28% 
reported to the companies.   
 A total of 34% respondents revealed that they neither had any information on current 
ADR reporting systems established in the area, nor had they any past knowledge in regards to 
ADR reporting systems. However, they all exercised knowledge of the country's guidelines 
and/or regulations pertaining to ADR reporting. Most of the respondents gathered information 
on ADR systems either verbally from colleagues (30%) or through Continuing Medical 
Education (CME) programs (23%).  A total of 28% respondents were willing to update their 
knowledge with respect to the guidelines and/or regulations on ADR reporting. (See Table 3). 
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Table 3: Showing responses to questions 1-5 in section A (n=47  unless specified). 
S. no Questions Yes NO Does not apply/do not 
remember / not sure 
1 Have you observed ADRs in 
the past 12 months? 
33 14  
2 Did you diagnose ADRs in the 
past 12 months? 
27 10 10 
3 Did you report ADRs to 
Pharmacovigilance centers or 
companies? 
21 26  
4 Would you like ADR reporting 
be made mandatory on part of 
doctors? (n= 41) 
 
28 4 9 
5 Did you receive any 
information regarding ADR 
reporting in the past 12 
months/ have you had past 
knowledge with regards to it ? 
30 16 1 
 
 On the contrary, only 28 (68.2%) subjects liked the idea of ADR reporting being made 
mandatory, while 4 (9.7%) subjects did not like the idea, indicating the reason that they 
cannot devote time to report ADRs. Out of the 68.2% who liked the idea of ADR reporting be 
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made mandatory, most of them were inclined towards having their staff report ADRs to 
centers, while they themselves would diagnose and confirm ADRs. A total of 21.9% subjects 
were not sure if they would or would not like the idea of ADR reporting being made 
mandatory. Results are displayed graphically in Figure 3. 
Figure 3: Bar chart showing response to ADR being made mandatory (n=41). 
 
   Nine subjects explained why they did not have an ADR reporting system established 
at their clinics/hospitals. It was evident that some were not aware of the system. One subject 
pointed to the lack of support from health administration and lack of initiative from hospital 
management as the reason for not having an established ADR reporting system. Most of the 
subjects were willing to report ADRs with the support of a clinical pharmacist. 
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4.3  ADR reporting - Attitude and practice 
 
  It was evident from the survey that most of the subjects had positive attitudes towards 
ADR reporting. Most of the subjects felt that doctors should report ADRs themselves. A total 
of 30 (63.8%) respondents out of 47 believed in doctors reporting ADRs to either 
pharmacovigilance centers or the pharmaceutical companies. With one question cross-
referencing the reason for not having an established ADR reporting system at clinics/ 
hospitals, the response of 10 subjects (21%) was that they are justified in thinking that 
pharmacists should report ADRs.  The data is summarized and presented graphically in figure 
4. 
 
 
Figure 4: Bar graph representing the perspective of the subjects to ADR reporting being made 
mandatory on part of doctors. 
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4.4  Types of ADRs generally reported by subjects 
 
 Upon analysis, a significant difference was observed between the two groups 
(government and private practitioners) of doctors with regards to the type of reactions/medical 
occurrences they would generally report to either pharmacovigilance centers or 
pharmaceutical companies. 
 When asked if they would report any suspected serious reactions to an established 
product that they have observed, almost all the government doctors 27(96.4% within group) 
said they would definitely report such reactions, while only 1(3.6% within group) respondent 
said he/she might report such reactions. On the other hand, 14(73.7% within group) private 
practitioners answered they would definitely report and 5(26.3% within group) responded 
they might report (Table 4). 
 With regards to reporting all suspected reactions to new products,19 (67.9% within 
group) government doctors said they would definitely report and 9(32.1% within group) said 
they might report. It was observed that a total of 12(63.2% within group) private practitioners 
said they might report all new suspected reactions to new products, while only 7(36.8% 
within group) answered they would definitely report such reactions. There lies a significant 
difference between the government and private practitioners in this regard (Table 4). 
 Similar to the responses registered for the first question in this section, 27 (96.4% 
within group) government doctors answered they would definitely report all life-threatening 
reactions and only 1(3.6% within group) responded he/she might report them. On the 
contrary, there were 6(31.6% within group) private practitioners who said they might report 
the reactions despite them being life threatening (Table 4).  
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 Government doctors were consistent in their knowledge of what kind of reactions they 
feel should be reported, and a similar 27(96.4% within group) respondents said would 
definitely report reactions causing disability, and 1(3.6% within group) respondent said they 
might report reactions causing disability. 
 A mixed response was recorded when the subjects of this survey were asked if they 
definitely would, might or definitely would not report ADRs that cause initial or prolonged 
hospitalization. Close to 40% (within group) in either of the groups responded they might 
report such reactions, and specifically 3(15.8% within group) private practitioners said they 
definitely would not report such ADRs that cause initial or prolonged hospitalization. All the 
data were analyzed and summarized in Table 4.  
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Table 4: Chi-square analysis with calculated percentages within groups. 
s.n
o 
 
Type of 
ADRs 
Type 
Of 
doctor
s 
          Recorded responses  
 
Total 
 
Chi-
square 
value 
 
p-value 
 
  Df 
 
Definitely 
Would report 
Might 
Report 
Definitely 
Would not 
report 
1 Serious 
suspected 
reactions to 
established 
products 
Govt. 27  (96.4%) 
0.5 (SR) 
 1 (3.6%) 
- 1.4 (SR) 
      _ 28  
5.258 
 
0.022 
 
1 
Pvt. 14  (73.7 %) 
- 0.6 (SR) 
 5 (26.3%) 
1.7 (SR) 
      _ 19 
2  
All suspected 
reactions to 
new products 
Govt. 19 (67.9%) 
0.9 (SR) 
9 (32.1%) 
- 1.0 (SR) 
_  
28 
 
4.405 
 
0.036 
 
1 
Pvt. 7 (36.8%) 
- 1.1 (SR) 
12 (63.2%) 
1.2 (SR) 
_ 19 
3  
Life 
threatening 
reactions 
regardless of 
product age 
Govt. 27 (96.4%) 
0.6 (SR) 
1 (3.6%) 
-1.6 (SR) 
_  
28 
 
7.005 
 
0.08 
 
1 
Pvt. 13 (68.4%) 
-0.8 (SR) 
6 (31.6%) 
1.9 (SR) 
_  
19 
4 Disability 
(significant, 
persistent or 
permanent) - 
regardless of 
product age 
Govt. 27 (96.4%) 
0.5 (SR) 
1 (3.6%) 
-1.4 (SR) 
_  
28 
 
 
5.258 
 
 
0.22 
 
 
1 Pvt. 14 (73.7%) 
-0.6 (SR) 
5 (26.3%) 
1.7 (SR) 
_  
19 
5 Hospitalizati
on 
(initial or 
prolonged) 
regardless of 
product age 
Govt. 17 (60.7%) 
0.4 (SR) 
11 (39.3%) 
0.1 (SR) 
0 (0%) 
- 1.3 (SR) 
28  
4.803 
 
0.91 
 
2 
Pvt. 9 (47.11%) 
- 0.5 (SR) 
7 (36.8%) 
- 0.1(SR) 
3 (15.8%) 
1.6 (SR) 
19 
 
  (SR = Standard Residual, df = Degree of freedom ). 
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 From table-4, it can be inferred that the Chi-square significance between the 
government doctors and private practitioners, with regards to the type of ADRs they would 
generally report, was significant with n= 47, df=2,  (total ) χ²=26.729, p < 0.05. There was no 
significant difference though between the government doctors and private practitioners with 
regards to reporting such ADRs that lead to either initial or prolonged hospitalization, with a 
χ²= 4.803, p > 0.05 at a 2 level degree of freedom.   
 Though the Chi-square turned out to be significant for variables 1, 3 and 4, each of the 
2x2 tables had at least 2 cells with expected count  < 5 that make the data invalid. Upon 
observation, with a standard residual 1.7, 1.9 and 1.7 (all close to 2 ) respectively, these 
groups of private practitioners influenced this outcome. 
4.5   Factors that encourage ADR reporting 
  
 Reactions to new products and seriousness of the reactions were the two factors that 
encouraged ADR reporting as per the results. On the other hand, unusual reactions and degree 
of confidence in diagnosis of ADRs were not a major factor that influenced ADR reporting.  
 A total of 27(96.4% within group) government doctors felt that seriousness of the 
reactions to products does influence their reporting of ADRs, while a similar percentage, 14 
(94.7% within group) of private practitioners, felt the same. There was no significant 
difference between these two groups in this regard with a  χ² value of 2.156 at a 2 level degree 
of freedom and p > 0.05 (Table 5).  
 There was also no significant difference in the opinion of both groups regarding the 
influence of degree of confidence in the diagnosis of ADRs. A total of 8(28.6% within group) 
government doctors and 7(36.4 % within group) private practitioners felt there is no necessity 
Pharmacovigilance: A comparative study on ADR reporting in a random city in India                        36 
 
 
to report the degree of confidence in diagnosing ADRs and that it does not influence their 
reporting of ADRs. (Table 5). 
 However, there was a significant difference between government doctors and private 
practitioners regarding the influence of unusual reactions on reporting with a χ² value of 
7.404, p < 0.05 (n= 47). Table 5 illustrates the analysis of factors influencing ADR reporting. 
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Table 5: Chi-square analysis of factors that encouraged ADR reporting.  
 
S.no 
 
Factors 
 
Type of 
Doctors 
             Recorded responses  
Tot
al 
 
Chi-
square 
 
P- 
value 
 
   Df Not 
required 
Required Unsure 
1 Unusual 
reactions 
Govt. 1 (36%) 
-1.4 (SR) 
23 (82.1%) 
0.2 (SR) 
4 (14.3%) 
1.0 (SR) 
28  
 
7.404 
 
 
0.025 
 
 
2 Pvt. 5(26.3%) 
1.7 (SR) 
14 (73.7%) 
- 0.2 (SR) 
0 (0%) 
- 1.3 (SR) 
19 
2 Reactions 
to new 
products 
 
Govt. 0 (0%) 
- 1.3(SR) 
24 (85.7%) 
0.3 (SR) 
4 (14.3%) 
0.2 (SR) 
28  
4.749 
 
0.093 
 
2 
Pvt. 3(15.8%) 
1.6 (SR) 
14 (73.7%) 
- 0.3 (SR) 
2 (10.5%) 
- 0.3 (SR) 
19 
3 Seriousness 
of the 
reactions 
Govt. 1 (36%) 
0.5 (SR) 
27 (96.4%) 
0.0 (SR) 
0 (0%) 
- 0.8 (SR) 
28  
 
2.156 
 
 
0.340 
 
 
2 
Pvt. 0 (0%) 
- 0.6 (SR) 
18 (94.7%) 
0.0 (SR) 
1 (5.3%) 
0.9 (SR) 
19 
4 Degree of 
confidence 
on 
diagnosis of 
ADRs 
Govt. 8(28.6%) 
- 0.3 (SR) 
18 (64.3%) 
0.5 (SR) 
2 (7.1%) 
- 0.2 (SR) 
28  
 
2.432 
 
 
0.488 
 
 
3 Pvt. 7(36.8%) 
0.4 (SR) 
9 (47.4%) 
- 0.6 (SR) 
2 (10.5%) 
0.3 (SR) 
18 
(SR = Standard Residual, df = Degree of freedom ). 
 Similar to the earlier section, Chi-square turned out to be significant for the first 
variable despite an expected count of 4 cells < 5 (1.62). Cumulative χ² = 16.741, n = 47, p > 
0.05. 
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4.6   Factors affecting ADR reporting 
 
 Unavailability of ADR reporting forms was considered as one of the major factors 
affecting the overall reporting rate as represented by the data. However, the rest of the factors 
also turned out to be contributing to the low ADR reporting rate.  
 Chi-square association was found to be insignificant with a cumulative χ² =18.669, p > 
0.05, n = 47 except for variable (factor) 6, which turned out to be significant with χ² = 8.196, 
p < 0.05. But, the data would be consider invalid as none of the calculated  standard residuals 
were 2.0, and also for the 6 variables in question, the expected count was found to be a 
minimum of 2 cells less < 5.    
 However, for the sixth variable, the Chi-square was significant at p < 0.05 with a value  
8.196. But, there was not much difference in the standard residual value, and the private 
practitioners in particular contributed to the significance which reiterates the inequality in the 
distribution of the sample. Results are tabulated in table 6. 
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Table 6: Chi-square analysis of factors affecting the ADR reporting (system or practice) 
S. 
no 
 
Factors 
 
Type of 
Doctors 
                    Responses  
Tot
al 
 
Chi-
Square 
 
p- 
value 
 
   Df 
 
Agree 
 
Disagree 
Neither 
agree nor 
disagree 
1 System of 
reporting is 
too 
bureaucratic 
Govt. 7 (25%) 
- 0.1(SR) 
6 (21.4%) 
0.6 (SR) 
15 (53.6%) 
- 0.3 (SR) 
28  
0.979 
 
0.613 
 
2 
Pvt. 5 (26.3%) 
0.1 (SR) 
2 (10.5%) 
- 0.7 (SR) 
12 (63.2%) 
0.3 (SR) 
19 
2 Too busy to 
send an ADR 
report 
Govt. 1 (3.6%) 
- 1.1 (SR) 
15 (53.6%) 
0.0 (SR) 
12 (42.9%) 
0.6 (SR) 
28  
4.110 
 
0.128 
 
2 
Pvt. 4 (21.1%) 
1.4 (SR) 
10 (52.6%) 
0.0 (SR) 
15 (26.3 %) 
- 0.7 (SR) 
19 
3 Report 
forms not 
available 
when 
needed 
Govt. 14 (50%) 
- 0.8 (SR) 
11 (39.3%) 
- 0.6 (SR) 
3 (10.7%) 
- 0.3 (SR) 
28  
2.636 
 
0.268 
 
2 
Pvt. 5 (26.3%) 
- 1.0 (SR) 
11 (57.9%) 
0.7 (SR) 
3 (15.8%) 
0.4 (SR) 
19 
4 Feel that 
you would 
be exposed 
to legal 
liability by 
reporting an 
ADR 
Govt. 2 (7.1%) 
0.2 (SR) 
23 (82.1%) 
0.1 (SR) 
3 (10.7%) 
- 0.3 (SR) 
28  
0.305 
 
0.858 
 
2 
Pvt. 1 (5.3%) 
- 0.2 (SR) 
15 (78.9%) 
- 0.1 (SR) 
3 (15.8%) 
0.4 (SR) 
19 
5 Believe that 
only safe 
drugs are 
Govt. 1 (3.6%) 
- 0.9 (SR) 
24 (85.7%) 
0.2 (SR) 
3 (10.7%) 
0.4 (SR) 
28  
2.443 
 
0.295 
 
2 
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marketed Pvt. 3 (15.8%) 
1.1 (SR) 
15 (78.9%) 
- 0.2 (SR) 
1 (5.3%) 
- 0.5 (SR) 
 
19 
6 
 
Unsure how 
to report an 
ADR 
Govt. 7 (25%) 
1.4 (SR) 
17 (60.7%) 
0.1 (SR) 
4 (14.3%) 
- 1.2 (SR) 
28  
8.196 
 
0.017 
 
2 
Pvt. 0 (0%) 
- 1.7 (SR) 
11 (57.9%) 
- 0.1 (SR) 
8 (42.1%) 
1.4 (SR) 
19 
  
(SR = Standard Residual, df = Degree of freedom ). 
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                                                    Chapter 5: Discussion 
 
 In the interest of public safety, the formidable strength of ADR reporting systems is its 
ability to continuously and spontaneously collect all such undesired reactions associated with 
drugs throughout their life cycles. Though the concept of pharmacovigilance emerged in the 
mid 1900's, it has been observed, throughout the world, that many factors influence doctors in 
reporting ADRs, and often the reporting rate was low. 
 In India, the concept of pharmacovigilance is relatively new, compared to the other 
developed nations like the UK and USA. Despite reviewing the NPP in the year 2010, there 
was a predominant under-reporting of ADRs in India, according to studies by Rishi, Patel and 
Bhandari  (2012) and Karkhar and Bowelakar (2012). Other studies conducted in the cities of 
Mumbai, Mysore and Muzzafarnagar, as reported by Desai et al. (2011) have shown high 
knowledge but poor practices with regards to ADR reporting. This study was an attempt to 
understand and compare, between government doctors and private practitioners, the 
knowledge, attitudes and practices with regards to ADR reporting in a Tier-II city. This study 
has found that both the government and private doctors have an adequate knowledge and 
possessed positive attitudes towards ADR reporting systems, but their practices were poor 
(with some exceptions). 
 The overall response rate was 21.3%, which is less compared to other survey's 
administered by Desai et al.(2011), who documented a 61% response rate and another similar 
survey by Gupta and Udupa (2011) who reported a response rate of 77.2% (which were 
similar to rates documented in studies from Germany, United Kingdom, Italy, Nigeria and the 
Netherlands). But, the ratio of male to female respondents to this survey was comparable to 
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other studies that recorded similar frequencies of male and female participants. However, this 
response rate was indicative of the factors affecting the practice of ADR reporting by both 
groups of doctors. Having said that, this could be a rather satisfactory response rate following 
repeated reminders sent every two weeks, given the limitations of this study.  
 A total of 27 (57.4%) government doctors and 14 (29.7%) private doctors responded 
to this survey. The comparison could have been effective had the percentage of respondents in 
the private practitioners group increased. It was understood that many doctors working in the 
government run hospitals also had a private practice of their own, but instead, chose to be 
identified as government doctors. A choice was given in this regard to study subjects in the 
study consent: if they wished to be identified as a private practitioner or as a government 
doctor when they fulfilled both, and as a result we see a higher number of responses registered 
in the group of government doctors. 
 The average practice experience of government doctors was high with 6.75 years of 
experience, while the private practitioners only had an average of 3.5 years of experience 
(Figure1). This could be attributed to the fact that government institutions (hospitals/clinics) 
relied on experienced doctors to treat patients in need of treatment and believed that the more 
the experience, the greater the skill a doctor has. An interesting observation was that there was 
a greater number of female government doctors with greater than 10 years of experience 
compared to male doctors. Many of the private practitioners had an experience ranging 
between 1-10 years, and there were only two private practitioners who reported they had 
greater than 10 years of experience (Table 2). A proper statistic, with regards to this 
difference in the experience gained, could only be obtained with a bigger sample size. 
Nonetheless, it had been observed that knowledge of ADRs and their reporting systems is 
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directly proportional to the experience gained through years of medical practice, based on a 
report by Upadhyaya et al. (2012) who stated that medical students had poor knowledge of 
ADRs/their reporting systems, while in another study, Rehan, Vasudev and Tripathi (2002), 
stated a need to incorporate a detailed concept of pharmacovigilance in the undergraduate 
medical curricula besides periodically strengthening this concept among the doctors.  
 Though the sample population was selected randomly (Figure 2), there were only a 
few respondents from specializations like cardiology, oncology, neurology etc. where there is 
large scope for occurrence of ADRs, owing to the fact that drugs used in the treatment of 
cardiovascular events or cancers or neuronal disorders are often potent chemical entities and 
exert a wide range of undesirable effects on the organ system and/or body. This low response 
to the survey from doctors belonging to these super-specialties might be due to their busy 
schedules. However, in the context of ADR reporting, it is important to devote quality time in 
reporting all those ADRs associated with the prescribed drugs despite busy schedules. 
 A majority of the doctors, indicated by the survey, observed less than 25 ADRs in a 
period of six months, which was a positive reflection on the knowledge, skill and awareness 
about ADRs among the doctors. However, only 57% of the doctors ever diagnosed ADRs and 
only 48% ever reported them. A majority (28%) of the respondents said they reported ADRs 
to pharmaceutical companies and only few reported ADRs to pharmacovigilance centers. This 
is a concern, as it reflects the failure of the NPP program. Few doctors reporting to 
pharmacovigilance centers might indicate poor knowledge with respect to the NPP program, 
which is consistent with the finding of 34% doctors' lack of information on the current ADR 
reporting systems established in the country. Though all the subjects of this study exercised 
adequate knowledge of the country's guidelines pertaining to ADR reporting, lack of 
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information on the current practices of ADR reporting reflects their low interests in reporting 
the otherwise burdensome ADRs. This emphasizes the need to extravagantly propagate the 
established NPP program and the ADR reporting systems by creating awareness among the 
prescribers of the program and the systems. This is possible by regularly organizing CME 
programs with an emphasis on pharmacovigilance as a majority of the study subjects stated 
their intention to update their knowledge with respect to the guidelines and/or regulations on 
ADR reporting via CME programs, indicating a broad scope for change in their present 
attitudes towards reporting ADRs. 
 On the contrary, only 48% of doctors reported ADRs to either pharmacovigilance 
centers or pharmaceutical companies which is comparatively low. In a pilot study conducted 
by Kharkar and Bowalekar (2012), 19% of their subjects were found to have reported 
diagnosed ADRs to ADR/pharmacovigilance centers while a majority of their respondents, 
(89.7%) were said to have reported ADRs to pharmaceutical companies/DGCI/ other NGO's 
who have a statutory obligation to report to the drug authorities concerned. These figures are, 
however, low compared to other countries like the UK where a high spontaneous ADR 
reporting rate was recorded. Also reporting rates in relation to prescription volumes was best 
among the European countries (Rishi et al., 2012). Ramesh and Parthasarathi (2009), 
estimated that only 10% of serious ADRs and 2-4% of non-serious ADRs are being reported, 
which is a rather high rate of under-reporting. Though doctors did not personally cite reasons 
for underreporting, they could be among the "seven deadly sins" summarized by Inman 
(1996) as :  
 Ignorance - not obtaining information on how to report ADRs despite their 
feeling that they are unsure how to report ADRs 
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 Diffidence - feeling foolish to report suspected ADRs 
 Fear of exposure to legal liability 
 Lethargy - being of the opinion that they are too busy to report ADRs 
 Guilt of unknowingly causing harm to the patient 
 Ambition of collecting the information on ADRs to publish them to their credit 
and 
 Complacency - being of the opinion that only safe drugs are marketed  
 Among these, lethargy could be assumed to be the reason for underreporting in this 
tier-II city, as there was a low response to this survey from doctors practicing super- 
specialties, as mentioned earlier, and also that there were 12.7% (6) responses registered by 
other medical/health care staff on behalf of the doctors they work for, though this survey was 
only administered to doctors. This indicates that the doctors were either ignoring to respond to 
the survey, or were too busy to respond, and hence had their staff answer the questionnaire. 
This is supported by the results that 9.7% (4) respondents did not like the idea of ADR 
reporting to be made mandatory on part of doctors (Table 3). 
 Interestingly, however, 68.2% respondents liked the idea of ADR reporting be made 
mandatory on part of doctors and 21.9% of them were not sure if they liked this idea, which 
was similar to the findings by Rishi et al. (2012). Out of the 68.2% who would like ADR 
reporting be made mandatory, many inclined toward taking the help of their support staff, 
especially clinical pharmacists, in reporting ADRs. This was inferred from the explanation of 
one of the respondents, who said, "An ADR reporting system need to be established at the 
clinic, with an office directly under the supervision of a clinical pharmacist." Another 
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respondent also stated the absence of clinical pharmacist in their clinic, as one of the reasons 
for not having an established ADR reporting system at their place.  
 This also indicates that most of the respondents (68.2%) had positive attitudes towards 
ADR reporting/systems, which is consistent with the findings in a study carried out by Rishi 
et al. (2012). The respondents' intention of the involvement of clinical pharmacists' in 
reporting ADRs, found in this study, was similar to a study conducted by Amrita and Roomi 
(2011) who reported, from various other studies, that for the success of pharmacovigilance 
programs involvement of pharmacists is essential. According to Grootheest et al. (2004), 
underreporting of ADRs could be lowered with considerable surveillance of the system by 
pharmacists. So, involving pharmacists in reporting ADRs can be considered pivotal in 
tackling the menace of underreporting in the first place. Pharmacists also play a major role in 
the detection of ADRs and contribute their part in reducing the occurrence of ADRs as found 
by Shulman, Shulman and Haines (1981). In their study, they found that pharmacists detected 
83 potential ADRs, and suggested general practitioners to change the prescription to avoid 
ADRs in another 53 cases. They also found pharmacists being instrumental in detecting 76 
unwanted prescription errors in their meta analysis of 1,366 patient medication records, 
collected over a period of 3 years, at a local pharmacy. They suggested that a closer 
collaboration between doctors and pharmacists would be mutually beneficial, while 
addressing the issue of ADRs. 
 In this study, a significant difference was observed ( N= 47, df= 2, [total] χ²= 26.729, p 
< 0.05) between the government doctors and private practitioners with regards to the 
knowledge they possess about ADRs and ADR reporting systems. The government doctors 
had, comparatively, more knowledge about the types of ADRs that need to be reported than 
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the private practitioners. However, it appears that both government and private doctors need 
to reinforce their knowledge on the current systems of ADR reporting and keep themselves 
abreast of knowledge with regards to the types of ADRs associated with drugs they usually 
prescribe. Most of the respondents from either group, if not few, said they might report, or 
definitely would not report, drug reactions causing initial or prolonged hospitalization. In this 
regard, there is a definite need to make these doctors understand the economic burden caused 
by such hospitalizations on the state government or health administration. It is important to 
note that in the year 2007, the average cost per ADR per patient was calculated to be ₹ 481 
(£6) by Arulmani et al. On the contrary, this difference could not be taken for granted, as a 
particular cell in the 2X2 table (Table 4) represents a group of private practitioners who 
influenced the outcome. As such, a definite statistic eliminating such influences could only be 
obtained with a larger sample size or a greater number of responses. 
 While most of the doctors identified reactions to new products and seriousness of the 
reactions as factors while reporting ADRs, many private practitioners did not consider 
unusual reactions to products worth reporting, which most of the time could turn out to be 
serious ADRs associated with drugs (Table 5). In this regard, government doctors had a good 
knowledge. These findings were in contrast with those in the study conducted by Rishi et al. 
(2012) where physicians were found to be more likely to report suspected ADRs for serious, 
unknown reactions/events for new drugs (81%) and serious, unknown reactions for 
established drugs (73%). When assessing the factors considered to affect the ADR reporting 
by doctors (Table 6), unavailability of ADR report forms, feeling that the system is too 
bureaucratic and busy schedules were cited predominantly, which are in line with the findings 
of Rishi et al. (2012) where 22.3% of respondents cited their busy schedules as reason for 
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underreporting and 2.1% of respondents cited the bureaucratic system as being the reason. 
Interestingly 8.5% (4) respondents believed only safe drugs are marketed, while a vast 
majority thought not all marketed drugs are safe. This obviously warrants a need to strictly 
enforce pharmacovigilance in their practice. Though many considered all marketed drugs are 
not safe, underreporting of ADRs still exist. 
 These results suggest a need to improve the practice of pharmacovigilance in the best 
interest of public safety in this tier-II city. With an insight into the factors affecting ADR 
reporting, there could be a possibility to come up with suggestions that might help improve 
the present trend in pharmacovigilance in this tier-II city of Warangal, of course with the 
limited information gathered via this survey. Some of the suggestions are: 
 Offering incentives to doctors for regularly reporting ADRs. This will 
definitely up-gear the practice of reporting, as many doctors think devoting 
time to reporting ADRs might, in a way, affect their time spent in earning 
money 
 Periodically conducting CME programs with good emphasis on the concept of 
Pharmacovigilance and the concept of ADRs. It can be observed from the 
results that about 28% of the respondents stated their willingness to update 
their knowledge through CME programs. This in particular, will have an 
immense response as many doctors do attend CME's to update their medical 
knowledge 
 Establishing spontaneous ADR reporting systems (electronic/paper - like the 
yellow card system established by the CSM in UK) in hospitals and clinics and 
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offering training, in the first place, on the working of such systems to doctors 
and their medical staff 
 Assuring all the doctors that they will not be held legally liable for 
discrepancies in any such ADR reports 
 Improving the system of pharmacies from merely filling prescriptions and 
dispensing to taking part in decision making during writing prescriptions as a 
primary care team member (Amrita and Roomi, 2011) 
 Offering clinical pharmacists good training in ADRs and their reporting 
systems and also incorporating the same in their curricula. Clinical 
Pharmacists often make good supervisors for ADR reporting systems given 
their knowledge about drugs and their interactions (Amrita and Roomi, 2011) 
  Periodically sending feedback to reporters on all the data gathered by NPP. 
This will definitely have a positive impact as it gives assurance to all the 
reporters that each and every ADR report is being considered, in-turn, to 
update their knowledge. Doing so will also improve the working of NPP, 
ultimately paving  the way to its success (Amrita and Roomi, 2011) 
 Sending warning letters or notifications to doctors regarding serious ADRs 
associated with drugs, immediately upon obtaining information from drug 
authorities/Pharmacovigilance centers (Amrita and Roomi, 2011) 
 Educating patients about ADRs and encouraging them to participate directly in 
spontaneous ADR reporting. As it is believed that patients themselves will 
have a better understanding of how ADRs / related events affect their lives/life 
styles (Blekinsopp, Wilkie, Wang and Routledge, 2006) 
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                                          Chapter 6 : Conclusion 
 
 There is a significant difference between government doctors and private practitioners 
in the tier-II city of Warangal, with regards to the knowledge of ADR reporting systems. 
Government doctors exhibited good knowledge of ADRs and current ADR reporting systems 
established in the nation, while private practitioners had a little knowledge of current systems 
in place. However, all the doctors surveyed do have knowledge of the guidelines and/or 
regulations pertaining to ADR reporting in India. Both groups of doctors had positive 
attitudes towards reporting ADRs, as a majority of them were open to the idea of ADR 
reporting being made mandatory on the part of doctors. However, some of them inclined 
towards having their support staff  like pharmacists and/or nursing staff, report ADRs on their 
behalf which was also evident from 6 responses registered by non doctors in a survey drafted 
only for doctors. There is a need to improve the concept of pharmacovigilance in this city, 
which requires  the participation of CDSCO via the NPP program.  
 The underreporting of ADRs in this city can be attributed to several factors as 
discussed earlier, but it would be inappropriate to generalize those factors and suggest ways to 
improve the situation based on a pilot study like this, which has certain limitations according 
to Launiala (2009). This was evident when a smaller group of private practitioners influenced 
the statistics. However, implementing the discussed suggestions would surely improve ADR 
reporting in this city, by motivating doctors to rigorously participate in pharmacovigilance 
programs in the best interest of public safety. There is also a need to conduct more research, 
with a larger sample size, including the adjacent cities, to the immediate North and South of 
this City. This would give a good sample size of doctors as these cities make the central zone 
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of the District of Warangal. Also, with a larger sample size, there is a possibility of a greater 
response rate and close to equal participation within both the groups of doctors. 
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Appendix A : Survey Questionnaire 
   Eastern Michigan University 
                CLRA 692 
                      Questionnaire for proposed research survey in a random locality in India 
 
Demographics: 
1- Gender         Male                                   Female 
 
2- Educational Qualifications of the person completing questionnaire. 
 Medicine     Pharmacy 
 Nursing       Others, Please Specify _________________. 
 
3- If a Physician, which Board of classification best describes your current area of 
practice? 
                                 a.General medicine                       b.Obstetrics&Gynecologist 
                                 c. Surgery                                       d. Pediatrics 
                                 e.Psychiatry                                   f.Other’s, please specify  
                                   gNot Board certified                    h.Does not apply 
 
4-  Type of practice? 
a.       Private 
b.       Government appointed 
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5- How long have you been practicing? 
a. < 1 year                      b.  1-5 years   
c.  5-10 years                  d. > 10 years 
      Section A: Adverse Drug Reaction (ADR) Reporting 
1- During the past 12 months, have you observed any adverse drug reaction with any 
drug? 
a. Yes                  b.  No 
2- If a Physician, have you ever diagnosed an adverse drug reaction in a patient under 
your care in the past 12 months? 
                       a. Yes                  b.  No      c.Does not apply 
                        If yes, on an average how many ADRs would be diagnosed under your care in 
a       period of 6 months?  
a. < 25                    b. 25 - 75 
c.  75 -125                  d. > 125 
 
3- During the past 12 months have you reported an ADR either to a Pharmacovigilance 
center or a Pharmaceutical Company? 
            a. Yes                                b.  No. 
 
             4- To whom did you send adverse drug reaction reports? 
a. To nearest Pharmacovigilance centers 
b.  To pharmaceutical company 
c.  Both 
 
5- Did you receive any information regarding ADR reporting in the past 12 months or 
have you had past knowledge of ADR reporting system? 
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a. Yes                   b.  No         c. Do not remember 
 
                               If yes, what type of information? 
                                    Written information in medical handbooks 
                                   Verbal information from colleagues 
                                   Through CEP programs 
 
If  No, Are you familiar with your country’s Guidelines and/or regulations pertaining to 
ADR  Reporting? 
 
                               a. Yes                   b.  No          
 
 If No, Would you consider updating your knowledge about your countries’       
established system of ADR reporting through CEP programs? 
                  a. Yes                   b.  No          
 
6- If you have a private practice, do you have any established ADR reporting system at 
your clinic?  
                 a. Yes                   b.  No          c.Does not apply 
 
                If No, What was the reason for not having an ADR reporting system in place 
at your clinic?  Please specify_______________________________________ 
 
 
_____________________________________________________________________
__. 
Please proceed to section C. 
Section B: ADR System at hospital/clinic 
7- How long current ADR system has been operating in your hospital/ clinic? 
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a. < 1 year                      b. 1-2 years 
c.  2-5 years                   d. > 5 years 
 
8- Are records of ADR reports stored in the hospital/clinic? 
                     a. Yes                   b.  No             c. Do not know 
 
9- Does your system involve screening laboratory results to detect ADRs? 
                    a. Yes                   b.  No             c. Do not know 
 
10- Are ADR reporting forms available in the hospital? 
a. Yes                   b.  No 
11-Is there any acknowledgement for reporting an ADR in your hospital? 
a. Yes                    b. No 
12- Who is the person responsible for screening ADR reports and  
           Submitting the same to the nearest Pharmacovigilance Centre? 
                              a.   Doctors          b.  Pharmacists 
                               c.   Nurse            d. Other (specify) 
                                 e.   Do not know 
Section C: Type of ADR’s you would generally report to either Pharmacovigilance centers or 
Pharmaceutical companies (who manufacture the product that causes such ADRs)? 
s.no              Types of ADRs Definitely 
would 
report  
Might 
report 
Definitely 
would not 
report 
 
1.                                      
 
Serious suspected reactions to 
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established products 
2. All suspected  reactions to new 
products 
   
666 3. 
667  
 Life-threatening reactions (risk of 
death)regardless of product age 
   
    4. Disability (significant, persistent 
or permanent) regardless of 
product age 
   
     5. Hospitalization (initial or 
prolonged)regardless of product 
age 
   
 
Section D: Which of the following factors do you think are required to be submitted in an 
ADR 
Report? 
S.no Factors Required Not required Unsure 
1.  
Unusual reactions 
   
2. Reaction to new products 
 
   
3. Seriousness of the reactions 
 
   
4. Degree of confidence in diagnosis of 
ADR 
 
   
 
 
Section E: Factors that pose as a hindrance to you in reporting ADRs? 
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s.no Factors 
 
Agree Neither 
agree nor 
Disagree 
Disagree 
 
1. 
 
System of reporting too bureaucratic 
 
   
 
2. 
 
Too busy to send an ADR reports 
 
   
 
3. 
 
Report form not available when needed 
 
   
 
4. 
 
Feel that you would be exposed to legal 
liability by reporting an ADR 
 
   
 
5. 
 
You believe that only safe drugs are 
marketed 
 
   
 
6. 
 
Unsure how to report an ADR 
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                                                                       Appendix C : Cover Letter 
 
Good Morning ! 
 
I am Shanthan Pingili, pursuing my MS in Clinical Research Administration at Eastern 
Michigan University (USA) and as part of my Thesis I've proposed a survey research here in 
India. My survey is designed to compare the knowledge of ADR reporting system that private 
and government doctors have gained and also to assess the factors that affect the proper 
functioning of the above said system in this tier-2 city of Warangal.  
 
You were randomly selected for this survey and I request your participation. The 
questionnaire is self-explanatory and should not take more than 5 - 10 minutes to answer. This 
is an anonymous survey and no identifying information, what so ever, is being requested. This 
is an absolutely no risk survey and your esteemed participation will help in understanding the 
current status of ADR reporting system in this city of Warangal. To collect valuable statistical 
data, government doctors who also practice privately, can wish to be identified either as a 
government doctor or as a private practitioner. 
The responses registered prior to December 15,  2012 are considered for data analysis. All 
subjects who register their responses are deemed as included in this study. If you wish not to 
participate in this survey, do not register your responses and are deemed as excluded from this 
survey study. 
 Below is the Link for the survey questionnaire: 
Pharmacovigilance: A comparative study about the knowledge of Adverse Drug Reaction 
(ADR) reporting that Private practitioners and Govt. Doctors gained in a random locality in 
India. 
https://docs.google.com/spreadsheet/viewform?formkey=dDZBZjI4ek5uT3I0ZGtUd2FfeVBo
aWc6MQ 
In case you lost the link, email me at shanthan.bharadwaj@gmail.com and I will re-send the 
link to this survey. 
Thank You for your time and support. 
 
PN: your advice/suggestions regarding this survey is sincerely appreciated. 
 
Regards 
Shanthan B Pingili 
MS in clinical Research Administration 
Eastern Michigan University
 
 
 
 
